LQDA touts commercial growth and expanding clinical pipeline
YUTREPIA launch drove rapid revenue and patient growth, with adoption in PAH and PH-ILD. The company says its pipeline is expanding, including L606 for broader indications and improved tolerability, supporting sustained profitability.
YUTREPIA's launch has driven rapid revenue and patient growth, with strong adoption in both PAH and PH-ILD. The pipeline is expanding with multiple clinical trials, including L606, targeting broader indications and improved tolerability. Financial performance is robust, with a focus on sustained pr…